Quantum BioPharma closes $56 insider placement that lifts founder voting power
What's the deal? Quantum BioPharmaDealroom has a profile for this one. Try Dealroom → has closed a non-brokered private placement of 26 Class A multiple-voting shares at US$2.28 each, raising gross proceeds of US$59.3 (roughly $56). The buyers were Fortius Research and Trading Corp. and the Xorax Family Trust, entities linked to chief executive officer Zeeshan Saeed and director Anthony Durkacz.
What does the company do? Quantum is a biopharmaceutical company developing treatments for neurodegenerative and metabolic disorders and alcohol misuse. Its lead candidate, Lucid-MS, targets the myelin degradation that underlies multiple sclerosis.
Why it matters: The placement is not operating finance. Each Class A share carries 276,660 votes, so the sale lifts the class's voting power to about 68.2%, consolidating control with insiders.
The context: It extends a pattern of small insider-linked placements used to concentrate votes. By contrast, a March 2026 convertible-debenture financing raised US$2.75M in real capital.
What else happened? At its annual meeting on November 10, 2026, shareholders backed all resolutions, with director elections exceeding 97% approval. They also re-appointed auditors, approved an equity incentive plan, and authorised a share consolidation and name change.
Class A holders represented 100% of multiple-voting shares; Class B holders represented 53.7% of their class. Together they accounted for about 71.9% of voting power on matters where Class A shares voted.
The signal: The 97% approval reads less as broad investor endorsement than as a reflection of a dual-class structure that hands founders control. The tiny placement reinforces that governance arithmetic rather than funding the pipeline.
Read more: agoracom.com
Image credit: Generated with Gemini
